Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Part of paid clinical trials in New York, New York.

Sponsor
Regeneron Pharmaceuticals
Study ID
NCT00083213
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.

Key Dates

Start date
Jan 31, 2004
Status verified
Jun 2016
Primary completion
May 31, 2008

Study Design

Enrollment
25 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Memorial Sloan - Kettering Cancer CenterNew YorkNew York10021-

Find similar trials in New York, NY

By research site
Memorial Sloan - Kettering Cancer Center· New York, NY

Related Studies